<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422162</url>
  </required_header>
  <id_info>
    <org_study_id>10614</org_study_id>
    <secondary_id>F1J-BI-HMES</secondary_id>
    <nct_id>NCT00422162</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression</brief_title>
  <official_title>An Eight-Week, Randomized, Double Blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 Per Day in Patients Hospitalized for Severe Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      An eight-week, randomized, double blind, two parallel groups, study to assess clinical
      response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for
      severe depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 4 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-Item Hamilton Depression Scale (HAMD-6) Total Scores From Baseline</measure>
    <time_frame>Baseline to Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The HAMD-6 (Items 1,2,7,8,10,13 from the 17-item HAMD) evaluates &quot;core&quot; symptoms of Major Depressive Disorder (MDD). Total scores range from 0 (normal) to 22 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline</measure>
    <time_frame>Baseline to Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Rescue Options Based on Changes in the Montgomery-Asberg Depression Rating Scale (MADRS) and the 6-Item Hamilton Depression Scale (HAMD-6)</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Changes in Montgomery-Åsberg Depression Rating Scale (MADRS) and 6-Item Hamilton Depression Scale (HAMD-6) total scores were evaluated following dose up-titration in those patients who did not achieve the minimum 50% response for primary endpoint. MADRS is a rating scale for severity of depressive mood symptoms. Total scores range from 0 (low severity of symptoms) to 60 (high severity of symptoms). The HAMD-6, derived by the sum of HAMD-17 items 1, 2, 7, 8, 10 and 13, evaluates &quot;core&quot; symptoms of Major Depressive Disorder (MDD). Total subscale scores range from 0 (normal) to 22 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity (CGI-S) Scores at Each Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) at Each Visit</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>Measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) Score at Each Visit</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAMA) Score at Baseline and Weeks 4 and 8</measure>
    <time_frame>Baseline and Weeks 4 and 8</time_frame>
    <description>The HAMA scale measures anxiety symptoms accompanying Major Depressive Disorder (MDD). Each item of the 14-item HAMA was scored from 0 (not present) to 4 (very severe), with a resulting maximum total score of 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>4 to 8 weeks</time_frame>
    <description>Patients with reduction in MADRS score ≥50% after 4 weeks were to stay on previous dose of duloxetine. Those with reduction in MADRS &lt;50% were to receive 120 mg for remaining 4 weeks of treatment (up-titration from 60 mg to 120 mg for those randomized to 60 mg, and addition of placebo to 120 mg dose for those randomized to 120 mg). However, 2/70 patients randomized to 60 mg and then up-titrated to 120 mg after 4 weeks had reduction in MADRS ≥50% after 4 weeks, and 3/64 patients randomized to 120 mg and then given placebo in addition after 4 weeks had reduction in MADRS ≥50% after 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Reaching Remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Major Depressive Disorder remission was defined as a total MADRS score ≤12 at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for Living (RFL) Questionnaire Mean Scores at Baseline and Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The RFL questionnaire is an instrument that evaluates patient's reasons for not committing suicide using a 6-point rating scale, where 1 is &quot;not at all important&quot; and 6 is &quot;extremely important&quot;. The questionnaire required participants to rate how important each item would be for living, if suicide was contemplated. Mean scores could range from 0 to 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utilization of Allowed Hypnotic and/or Anxiolytic Co-Medication</measure>
    <time_frame>over 8 weeks</time_frame>
    <description>Number of participants using medication for anxiety and sleep disturbances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Potentially Clinically Significant Laboratory Findings</measure>
    <time_frame>over 8 weeks</time_frame>
    <description>Laboratory results that were potentially clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations Due to Adverse Events (AE)</measure>
    <time_frame>over 8 weeks</time_frame>
    <description>Listing of adverse events (AE) that led to treatment discontinuation (DC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing High Values for Vital Signs at Any Time During the Study</measure>
    <time_frame>over 8 weeks</time_frame>
    <description>Systolic and diastolic blood pressure and pulse rate were measured after 2 minutes rest in a supine position. High values were: diastolic blood pressure ≥90 mm Hg and increase from baseline of ≥10 mm Hg; systolic blood pressure ≥140 mm Hg and increase from baseline of ≥10 mm Hg; pulse rate ≥100 beats per minute (bpm) and an increase of ≥10 bpm from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 and Week 8 in Weight</measure>
    <time_frame>Baseline to Weeks 4 and 8</time_frame>
    <description>Change in weight = Post-baseline visit minus baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Duloxetine Hydrochloride (60 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to Week 4: 60 milligrams (mg) every morning and placebo every evening, by mouth (PO).
Week 4 to Week 8: Responders continued on same dose as before; Nonresponders received 60 mg every morning and 60 mg every evening added to the placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine Hydrochloride (120 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to Week 4: 60 mg every morning and 60 mg every evening, PO.
Week 4 to Week 8: Responders continued on same dose as before; Nonresponders continued as before with a placebo capsule added to the evening dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine hydrochloride</intervention_name>
    <description>60 mg once or twice a day, by mouth</description>
    <arm_group_label>Duloxetine Hydrochloride (60 mg)</arm_group_label>
    <arm_group_label>Duloxetine Hydrochloride (120 mg)</arm_group_label>
    <other_name>LY248686</other_name>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsule by mouth</description>
    <arm_group_label>Duloxetine Hydrochloride (60 mg)</arm_group_label>
    <arm_group_label>Duloxetine Hydrochloride (120 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female patients of ≥ 18 years of age that meet criteria for severe Major Depressive
        Disorder, without psychotic features (according to Diagnostic and Statistical Manual of
        Mental Disorders Fourth Edition, [DSM-IV] and confirmed by Mini International
        Neuropsychiatric Interview [MINI]).

          -  With a total score Montgomery-Asberg Depression Rating Scale (MADRS) ≥ 30 and 6-item
             Hamilton Depression Rating Scale (HAMD-6) ≥ 12 and Clinical Global Impression of
             Severity (CGI-Severity) ≥ 4 at both screening and baseline.

          -  Requirement of hospitalization (not for social or other non-medical reasons) at
             screening visit and at least up to Visit 4.

          -  Patients willing and able to comply with the requirement for hospitalization and with
             all scheduled visits, tests and procedures required by the protocol.

          -  Informed consent document must be signed at screening visit, in accordance with Good
             Clinical Practice (GCP) and local regulatory requirements, prior to any study
             procedure.

        Exclusion Criteria:

          -  More than two previous episodes of major depression that did not respond (according to
             investigator's opinion) to adequate doses and duration of two different antidepressant
             therapies.

          -  Lack of response to at least two antidepressant therapies given at adequate doses for
             at least 6 weeks for the current depressive episode.

          -  Concurrent presence of symptoms fulfilling criteria for any Axis I disorder other than
             anxiety disorders (with exception of the Obsessive-Compulsive Disorder (OCD)) or Major
             Depressive Disorder, in the investigator's judgment.

          -  Any previous diagnosis of a bipolar disorder, schizophrenia or OCD.

          -  Depression with catatonic features (according to DSM-IV), depression with post-partum
             onset, or organic mental disorders.

          -  The presence of an Axis II disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Bully les Mines</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Chateau-Gontier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Dole</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Fains Veel</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Jarnac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>La Charite sur Loire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Montberon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Saint-Dizier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Bryanston</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559), Mon-Fri, 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <results_reference>
    <citation>Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. J Clin Psychiatry. 2011 Aug;72(8):1086-94. doi: 10.4088/JCP.09m05723blu. Epub 2010 Sep 21.</citation>
    <PMID>20868642</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <results_first_submitted>August 25, 2009</results_first_submitted>
  <results_first_submitted_qc>August 25, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2009</results_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 392 patients who signed informed consent, 339 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine (60 mg)</title>
          <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Duloxetine (120 mg)</title>
          <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliant with Protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Didn't Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine (60 mg)</title>
          <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Duloxetine (120 mg)</title>
          <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="167"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="338"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="13.9"/>
                    <measurement group_id="B2" value="43.9" spread="12.7"/>
                    <measurement group_id="B3" value="44.8" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Major Depressive Disorder Episodes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at First Major Depressive Episode</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="13.3"/>
                    <measurement group_id="B2" value="35.6" spread="12.4"/>
                    <measurement group_id="B3" value="36.0" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118.7" spread="12.4"/>
                    <measurement group_id="B2" value="119.4" spread="14.8"/>
                    <measurement group_id="B3" value="119.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.6" spread="8.5"/>
                    <measurement group_id="B2" value="74.7" spread="8.2"/>
                    <measurement group_id="B3" value="74.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body mass index is an estimate of body fat based on body weight in kilograms divided by height in meters squared.</description>
          <units>kilograms/square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="5.5"/>
                    <measurement group_id="B2" value="25.5" spread="5.5"/>
                    <measurement group_id="B3" value="25.3" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Previous Major Depressive Disorder (MDD) Episode</title>
          <description>Duration of previous MDD episode in participants who experienced a previous MDD episode.</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.4" spread="19.0"/>
                    <measurement group_id="B2" value="13.7" spread="11.3"/>
                    <measurement group_id="B3" value="15.0" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.1" spread="8.1"/>
                    <measurement group_id="B2" value="166.5" spread="7.6"/>
                    <measurement group_id="B3" value="166.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Hospitalizations</title>
          <description>Number of hospitalizations for MDD in participants who experienced previous MDD episodes.</description>
          <units>number of hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="1.6"/>
                    <measurement group_id="B2" value="1.5" spread="2.3"/>
                    <measurement group_id="B3" value="1.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Major Depressive Disorder (MDD) Episodes</title>
          <description>Number of previous MDD episodes for participants who experienced previous MDD episodes.</description>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="2.7"/>
                    <measurement group_id="B2" value="3.1" spread="3.0"/>
                    <measurement group_id="B3" value="3.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulse Rate</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" spread="8.8"/>
                    <measurement group_id="B2" value="75.8" spread="9.2"/>
                    <measurement group_id="B3" value="75.9" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="16.7"/>
                    <measurement group_id="B2" value="70.6" spread="15.2"/>
                    <measurement group_id="B3" value="70.5" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 4 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
        <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
          <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="4.0"/>
                    <measurement group_id="O2" value="36.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.1" spread="10.6"/>
                    <measurement group_id="O2" value="-19.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>P-value for Change from Baseline. A priori alpha threshold was 0.05 with no adjustment for multiple testing.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with stratification factors (country and pretreatment for MDD) and MADRS baseline as covariates and treatment regimen as the main factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6-Item Hamilton Depression Scale (HAMD-6) Total Scores From Baseline</title>
        <description>The HAMD-6 (Items 1,2,7,8,10,13 from the 17-item HAMD) evaluates &quot;core&quot; symptoms of Major Depressive Disorder (MDD). Total scores range from 0 (normal) to 22 (severe).</description>
        <time_frame>Baseline to Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg Responder</title>
            <description>60mg QD for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Non-Responder</title>
            <description>60mg QD for 4 weeks then 60mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 120 mg Responder</title>
            <description>60mg BID for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 120 mg Non-Responder</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4)</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg (All)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>Duloxetine 120 mg (All)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6-Item Hamilton Depression Scale (HAMD-6) Total Scores From Baseline</title>
          <description>The HAMD-6 (Items 1,2,7,8,10,13 from the 17-item HAMD) evaluates &quot;core&quot; symptoms of Major Depressive Disorder (MDD). Total scores range from 0 (normal) to 22 (severe).</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="166"/>
                <count group_id="O6" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Score at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="3.7"/>
                    <measurement group_id="O2" value="-1.9" spread="3.2"/>
                    <measurement group_id="O3" value="-3.3" spread="3.4"/>
                    <measurement group_id="O4" value="-1.7" spread="2.7"/>
                    <measurement group_id="O5" value="-3.1" spread="3.6"/>
                    <measurement group_id="O6" value="-2.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="4.4"/>
                    <measurement group_id="O2" value="-3.4" spread="3.6"/>
                    <measurement group_id="O3" value="-6.5" spread="4.2"/>
                    <measurement group_id="O4" value="-3.0" spread="3.1"/>
                    <measurement group_id="O5" value="-5.8" spread="4.6"/>
                    <measurement group_id="O6" value="-5.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="3.7"/>
                    <measurement group_id="O2" value="-4.1" spread="3.4"/>
                    <measurement group_id="O3" value="-8.7" spread="3.6"/>
                    <measurement group_id="O4" value="-3.6" spread="3.7"/>
                    <measurement group_id="O5" value="-7.2" spread="4.4"/>
                    <measurement group_id="O6" value="-6.8" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="3.2"/>
                    <measurement group_id="O2" value="-3.9" spread="3.3"/>
                    <measurement group_id="O3" value="-10.7" spread="3.0"/>
                    <measurement group_id="O4" value="-3.8" spread="3.6"/>
                    <measurement group_id="O5" value="-8.0" spread="4.8"/>
                    <measurement group_id="O6" value="-8.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="3.5"/>
                    <measurement group_id="O2" value="-6.4" spread="4.4"/>
                    <measurement group_id="O3" value="-11.8" spread="3.3"/>
                    <measurement group_id="O4" value="-5.5" spread="4.4"/>
                    <measurement group_id="O5" value="-9.4" spread="4.7"/>
                    <measurement group_id="O6" value="-9.4" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="3.4"/>
                    <measurement group_id="O2" value="-7.6" spread="5.1"/>
                    <measurement group_id="O3" value="-12.5" spread="3.0"/>
                    <measurement group_id="O4" value="-6.7" spread="5.4"/>
                    <measurement group_id="O5" value="-10.3" spread="4.8"/>
                    <measurement group_id="O6" value="-10.3" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline</title>
        <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
        <time_frame>Baseline to Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg Responder</title>
            <description>60mg QD for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Non-Responder</title>
            <description>60mg QD for 4 weeks then 60mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 120 mg Responder</title>
            <description>60mg BID for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 120 mg Non-Responder</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4)</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg (All)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>Duloxetine 120 mg (All)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline</title>
          <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="166"/>
                <count group_id="O6" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Score at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="8.6"/>
                    <measurement group_id="O2" value="-5.6" spread="6.2"/>
                    <measurement group_id="O3" value="-8.8" spread="7.6"/>
                    <measurement group_id="O4" value="-5.6" spread="6.3"/>
                    <measurement group_id="O5" value="-8.3" spread="8.0"/>
                    <measurement group_id="O6" value="-7.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" spread="9.9"/>
                    <measurement group_id="O2" value="-9.4" spread="7.1"/>
                    <measurement group_id="O3" value="-16.3" spread="8.4"/>
                    <measurement group_id="O4" value="-8.9" spread="7.7"/>
                    <measurement group_id="O5" value="-14.7" spread="9.9"/>
                    <measurement group_id="O6" value="-13.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.2" spread="8.4"/>
                    <measurement group_id="O2" value="-11.1" spread="6.8"/>
                    <measurement group_id="O3" value="-20.9" spread="6.9"/>
                    <measurement group_id="O4" value="-10.3" spread="9.1"/>
                    <measurement group_id="O5" value="-18.1" spread="9.8"/>
                    <measurement group_id="O6" value="-16.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" spread="6.5"/>
                    <measurement group_id="O2" value="-10.4" spread="6.9"/>
                    <measurement group_id="O3" value="-25.5" spread="5.6"/>
                    <measurement group_id="O4" value="-10.5" spread="8.6"/>
                    <measurement group_id="O5" value="-20.1" spread="10.6"/>
                    <measurement group_id="O6" value="-19.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.3" spread="7.9"/>
                    <measurement group_id="O2" value="-16.1" spread="9.4"/>
                    <measurement group_id="O3" value="-28.1" spread="6.6"/>
                    <measurement group_id="O4" value="-14.8" spread="10.4"/>
                    <measurement group_id="O5" value="-23.1" spread="10.4"/>
                    <measurement group_id="O6" value="-23.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Score at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.8" spread="7.3"/>
                    <measurement group_id="O2" value="-19.0" spread="11.8"/>
                    <measurement group_id="O3" value="-29.5" spread="6.6"/>
                    <measurement group_id="O4" value="-17.2" spread="12.3"/>
                    <measurement group_id="O5" value="-25.2" spread="10.8"/>
                    <measurement group_id="O6" value="-24.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Rescue Options Based on Changes in the Montgomery-Asberg Depression Rating Scale (MADRS) and the 6-Item Hamilton Depression Scale (HAMD-6)</title>
        <description>Changes in Montgomery-Åsberg Depression Rating Scale (MADRS) and 6-Item Hamilton Depression Scale (HAMD-6) total scores were evaluated following dose up-titration in those patients who did not achieve the minimum 50% response for primary endpoint. MADRS is a rating scale for severity of depressive mood symptoms. Total scores range from 0 (low severity of symptoms) to 60 (high severity of symptoms). The HAMD-6, derived by the sum of HAMD-17 items 1, 2, 7, 8, 10 and 13, evaluates &quot;core&quot; symptoms of Major Depressive Disorder (MDD). Total subscale scores range from 0 (normal) to 22 (severe).</description>
        <time_frame>4 to 8 weeks</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a Week 4 and at least one following value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg Responder</title>
            <description>60mg QD for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Non-Responder</title>
            <description>60mg QD for 4 weeks then 60mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 120 mg Responder</title>
            <description>60mg BID for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 120 mg Non-Responder</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4)</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Rescue Options Based on Changes in the Montgomery-Asberg Depression Rating Scale (MADRS) and the 6-Item Hamilton Depression Scale (HAMD-6)</title>
          <description>Changes in Montgomery-Åsberg Depression Rating Scale (MADRS) and 6-Item Hamilton Depression Scale (HAMD-6) total scores were evaluated following dose up-titration in those patients who did not achieve the minimum 50% response for primary endpoint. MADRS is a rating scale for severity of depressive mood symptoms. Total scores range from 0 (low severity of symptoms) to 60 (high severity of symptoms). The HAMD-6, derived by the sum of HAMD-17 items 1, 2, 7, 8, 10 and 13, evaluates &quot;core&quot; symptoms of Major Depressive Disorder (MDD). Total subscale scores range from 0 (normal) to 22 (severe).</description>
          <population>All randomized participants who received at least one dose of study drug and had a Week 4 and at least one following value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in MADRS Score from Week 4 to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="5.1"/>
                    <measurement group_id="O2" value="-7.2" spread="6.3"/>
                    <measurement group_id="O3" value="-2.6" spread="4.2"/>
                    <measurement group_id="O4" value="-5.8" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in MADRS Score from Week 4 to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="6.0"/>
                    <measurement group_id="O2" value="-10.9" spread="8.8"/>
                    <measurement group_id="O3" value="-4.0" spread="5.3"/>
                    <measurement group_id="O4" value="-8.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HAMD-6 Score from Week 4 to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.7"/>
                    <measurement group_id="O2" value="-3.2" spread="2.7"/>
                    <measurement group_id="O3" value="-1.1" spread="1.8"/>
                    <measurement group_id="O4" value="-2.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HMAD-6 Score from Week 4 to Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.8"/>
                    <measurement group_id="O2" value="-4.7" spread="3.6"/>
                    <measurement group_id="O3" value="-1.8" spread="2.4"/>
                    <measurement group_id="O4" value="-3.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Severity (CGI-S) Scores at Each Visit</title>
        <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Severity (CGI-S) Scores at Each Visit</title>
          <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
          <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.7"/>
                    <measurement group_id="O2" value="5.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.9"/>
                    <measurement group_id="O2" value="4.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.2"/>
                    <measurement group_id="O2" value="3.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.3"/>
                    <measurement group_id="O2" value="3.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.4"/>
                    <measurement group_id="O2" value="3.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.4"/>
                    <measurement group_id="O2" value="2.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.4"/>
                    <measurement group_id="O2" value="2.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Improvement (CGI-I) at Each Visit</title>
        <description>Measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Improvement (CGI-I) at Each Visit</title>
          <description>Measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).</description>
          <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.8"/>
                    <measurement group_id="O2" value="3.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.0"/>
                    <measurement group_id="O2" value="2.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.9"/>
                    <measurement group_id="O2" value="2.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.1"/>
                    <measurement group_id="O2" value="2.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.1"/>
                    <measurement group_id="O2" value="2.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.2"/>
                    <measurement group_id="O2" value="1.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) Score at Each Visit</title>
        <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) Score at Each Visit</title>
          <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
          <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=164, n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.0"/>
                    <measurement group_id="O2" value="3.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=164, n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.1"/>
                    <measurement group_id="O2" value="2.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=165, n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.1"/>
                    <measurement group_id="O2" value="2.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=165, n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.2"/>
                    <measurement group_id="O2" value="2.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=165, n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.3"/>
                    <measurement group_id="O2" value="2.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=165, n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.3"/>
                    <measurement group_id="O2" value="1.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Anxiety Scale (HAMA) Score at Baseline and Weeks 4 and 8</title>
        <description>The HAMA scale measures anxiety symptoms accompanying Major Depressive Disorder (MDD). Each item of the 14-item HAMA was scored from 0 (not present) to 4 (very severe), with a resulting maximum total score of 56.</description>
        <time_frame>Baseline and Weeks 4 and 8</time_frame>
        <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Anxiety Scale (HAMA) Score at Baseline and Weeks 4 and 8</title>
          <description>The HAMA scale measures anxiety symptoms accompanying Major Depressive Disorder (MDD). Each item of the 14-item HAMA was scored from 0 (not present) to 4 (very severe), with a resulting maximum total score of 56.</description>
          <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Baseline) (n=166, n=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="6.4"/>
                    <measurement group_id="O2" value="27.0" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=165, n=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="8.8"/>
                    <measurement group_id="O2" value="13.4" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=165, n=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="8.8"/>
                    <measurement group_id="O2" value="9.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders</title>
        <description>Patients with reduction in MADRS score ≥50% after 4 weeks were to stay on previous dose of duloxetine. Those with reduction in MADRS &lt;50% were to receive 120 mg for remaining 4 weeks of treatment (up-titration from 60 mg to 120 mg for those randomized to 60 mg, and addition of placebo to 120 mg dose for those randomized to 120 mg). However, 2/70 patients randomized to 60 mg and then up-titrated to 120 mg after 4 weeks had reduction in MADRS ≥50% after 4 weeks, and 3/64 patients randomized to 120 mg and then given placebo in addition after 4 weeks had reduction in MADRS ≥50% after 4 weeks.</description>
        <time_frame>4 to 8 weeks</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg Responders</title>
            <description>60mg QD for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Non-Responders</title>
            <description>60mg QD for 4 weeks then 60mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 120 mg Responders</title>
            <description>60mg BID for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 120 mg Non-Responders</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders</title>
          <description>Patients with reduction in MADRS score ≥50% after 4 weeks were to stay on previous dose of duloxetine. Those with reduction in MADRS &lt;50% were to receive 120 mg for remaining 4 weeks of treatment (up-titration from 60 mg to 120 mg for those randomized to 60 mg, and addition of placebo to 120 mg dose for those randomized to 120 mg). However, 2/70 patients randomized to 60 mg and then up-titrated to 120 mg after 4 weeks had reduction in MADRS ≥50% after 4 weeks, and 3/64 patients randomized to 120 mg and then given placebo in addition after 4 weeks had reduction in MADRS ≥50% after 4 weeks.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥50% Reduction in MADRS Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥50% Reduction in MADRS Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8"/>
                    <measurement group_id="O2" value="52.9"/>
                    <measurement group_id="O3" value="98.1"/>
                    <measurement group_id="O4" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥50% Reduction in MADRS Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="65.7"/>
                    <measurement group_id="O3" value="98.1"/>
                    <measurement group_id="O4" value="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥50% Reduction in HAMD-6 Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="85.8"/>
                    <measurement group_id="O4" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥50% Reduction in HAMD-6 Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="90.6"/>
                    <measurement group_id="O4" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥50% Reduction in HAMD-6 Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="95.3"/>
                    <measurement group_id="O4" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Reaching Remission</title>
        <description>Major Depressive Disorder remission was defined as a total MADRS score ≤12 at Week 8.</description>
        <time_frame>Week 8</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg Responders</title>
            <description>60mg QD for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Non-Responders</title>
            <description>60mg QD for 4 weeks then 60mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 120 mg Responders</title>
            <description>60mg BID for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 120 mg Non-Responders</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Reaching Remission</title>
          <description>Major Depressive Disorder remission was defined as a total MADRS score ≤12 at Week 8.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remission at Week 8 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission at Week 8 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reason for Living (RFL) Questionnaire Mean Scores at Baseline and Week 8</title>
        <description>The RFL questionnaire is an instrument that evaluates patient's reasons for not committing suicide using a 6-point rating scale, where 1 is &quot;not at all important&quot; and 6 is &quot;extremely important&quot;. The questionnaire required participants to rate how important each item would be for living, if suicide was contemplated. Mean scores could range from 0 to 6.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine 60 mg Responder</title>
            <description>60mg QD for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine 60 mg Non-Responder</title>
            <description>60mg QD for 4 weeks then 60mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Duloxetine 120 mg Responder</title>
            <description>60mg BID for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 120 mg Non-Responder</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4)</description>
          </group>
          <group group_id="O5">
            <title>Duloxetine 60 mg (All)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>Duloxetine 120 mg (All)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Reason for Living (RFL) Questionnaire Mean Scores at Baseline and Week 8</title>
          <description>The RFL questionnaire is an instrument that evaluates patient's reasons for not committing suicide using a 6-point rating scale, where 1 is &quot;not at all important&quot; and 6 is &quot;extremely important&quot;. The questionnaire required participants to rate how important each item would be for living, if suicide was contemplated. Mean scores could range from 0 to 6.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. Last observation carried forward. Participants were assigned their responder status at Week 4 and the data were retrospectively divided into these groups.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="166"/>
                <count group_id="O6" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Baseline) (n=96, n=66, n=106, n=61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.1"/>
                    <measurement group_id="O2" value="3.6" spread="1.0"/>
                    <measurement group_id="O3" value="3.7" spread="1.0"/>
                    <measurement group_id="O4" value="3.7" spread="1.0"/>
                    <measurement group_id="O5" value="3.8" spread="1.1"/>
                    <measurement group_id="O6" value="3.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=93, n=63, n=100, n=59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.9"/>
                    <measurement group_id="O2" value="4.0" spread="1.2"/>
                    <measurement group_id="O3" value="4.6" spread="0.9"/>
                    <measurement group_id="O4" value="3.8" spread="1.1"/>
                    <measurement group_id="O5" value="4.4" spread="1.1"/>
                    <measurement group_id="O6" value="4.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (n=93, n=59, n=100, n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.9"/>
                    <measurement group_id="O2" value="0.4" spread="0.8"/>
                    <measurement group_id="O3" value="0.8" spread="0.8"/>
                    <measurement group_id="O4" value="0.1" spread="0.9"/>
                    <measurement group_id="O5" value="0.6" spread="0.9"/>
                    <measurement group_id="O6" value="0.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for Change from Baseline (within group)</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value for Change from Baseline (within group)</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for Change from Baseline (within group)</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <p_value_desc>P-value for Change from Baseline (within group)</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Utilization of Allowed Hypnotic and/or Anxiolytic Co-Medication</title>
        <description>Number of participants using medication for anxiety and sleep disturbances.</description>
        <time_frame>over 8 weeks</time_frame>
        <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward. The total number of patients with hypnotics and anxiolytics concomitant therapies was 125 (Duloxetine 60mg) and 123 (Duloxetine 120mg).</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Utilization of Allowed Hypnotic and/or Anxiolytic Co-Medication</title>
          <description>Number of participants using medication for anxiety and sleep disturbances.</description>
          <population>All randomized participants who received at least one dose of study drug; had baseline and at least one post-baseline value. Last observation carried forward. The total number of patients with hypnotics and anxiolytics concomitant therapies was 125 (Duloxetine 60mg) and 123 (Duloxetine 120mg).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medication Taken Before Start of Study (Week -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Taken Between Week -1 and Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Taken Between Week 0 and Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Taken Between Week 1 and Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Taken Between Week 2 and Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Taken Between Week 3 and Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Taken Between Week 4 and Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Taken Between Week 6 and Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Taken After Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication Not Taken Between Consecutive Visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Potentially Clinically Significant Laboratory Findings</title>
        <description>Laboratory results that were potentially clinically significant.</description>
        <time_frame>over 8 weeks</time_frame>
        <population>All randomized participants with at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Potentially Clinically Significant Laboratory Findings</title>
          <description>Laboratory results that were potentially clinically significant.</description>
          <population>All randomized participants with at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased Haematocrit (n=155, n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Haemoglobin (n=156, n=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Red Cell Count (n=156, n=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Mean Cell Volume (n=155, n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased White Cell Count (n=156, n=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Sodium (n=160, n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Potassium (n=159, n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Aspartate Transaminase (n=158, n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Alanine Transaminase (n=159, n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Alkaline Phosphatase (n=161, n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Gamma-Glutamyl Transferase (n=161,n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Creatine Kinase (n=159, n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Glucose (n=158, n=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Cholesterol (n=160, n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Total Bilirubin (n=159, n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Uric Acid (n=160, n=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Albumin (n=158, n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuations Due to Adverse Events (AE)</title>
        <description>Listing of adverse events (AE) that led to treatment discontinuation (DC).</description>
        <time_frame>over 8 weeks</time_frame>
        <population>All randomized participants with at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Discontinuations Due to Adverse Events (AE)</title>
          <description>Listing of adverse events (AE) that led to treatment discontinuation (DC).</description>
          <population>All randomized participants with at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Number of Patients With AEs Leading to DC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypothyroidism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychotic Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizoaffective Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-Injurious Behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sedation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotonin Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug Eruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Retention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing High Values for Vital Signs at Any Time During the Study</title>
        <description>Systolic and diastolic blood pressure and pulse rate were measured after 2 minutes rest in a supine position. High values were: diastolic blood pressure ≥90 mm Hg and increase from baseline of ≥10 mm Hg; systolic blood pressure ≥140 mm Hg and increase from baseline of ≥10 mm Hg; pulse rate ≥100 beats per minute (bpm) and an increase of ≥10 bpm from baseline.</description>
        <time_frame>over 8 weeks</time_frame>
        <population>All randomized participants with at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing High Values for Vital Signs at Any Time During the Study</title>
          <description>Systolic and diastolic blood pressure and pulse rate were measured after 2 minutes rest in a supine position. High values were: diastolic blood pressure ≥90 mm Hg and increase from baseline of ≥10 mm Hg; systolic blood pressure ≥140 mm Hg and increase from baseline of ≥10 mm Hg; pulse rate ≥100 beats per minute (bpm) and an increase of ≥10 bpm from baseline.</description>
          <population>All randomized participants with at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Pulse Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 and Week 8 in Weight</title>
        <description>Change in weight = Post-baseline visit minus baseline.</description>
        <time_frame>Baseline to Weeks 4 and 8</time_frame>
        <population>All randomized participants with at least one dose of study drug and a baseline and at least one post-baseline value. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (60 mg)</title>
            <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine (120 mg)</title>
            <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 and Week 8 in Weight</title>
          <description>Change in weight = Post-baseline visit minus baseline.</description>
          <population>All randomized participants with at least one dose of study drug and a baseline and at least one post-baseline value. Last observation carried forward.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 4 (n=163,n=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.0"/>
                    <measurement group_id="O2" value="0.0" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8 (n=163, n=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.9"/>
                    <measurement group_id="O2" value="0.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine (60 mg)</title>
          <description>60mg every day (QD) for 4 weeks, then responders continued on same dose and nonresponders increased to 60mg twice a day (BID) for next 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Duloxetine (120 mg)</title>
          <description>60mg BID for 8 weeks (placebo added at Week 4 for nonresponders)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7"/>
                <counts group_id="E2" subjects_affected="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95"/>
                <counts group_id="E2" subjects_affected="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="42" subjects_affected="37" subjects_at_risk="167"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="37" subjects_affected="26" subjects_at_risk="167"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

